DRREDDY

DR. REDDY'S LABORATORIES

Large Cap BSE: 500124 NSE: DRREDDY
₹4260.8
2.5 (0.06%)
As on 14 August, 2022 | 11:04

Dr. Reddy's Laboratories Share Price

Dr. Reddy's Laboratories Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Dr. Reddy's Laboratories Share Returns

  • Over 1 Month -4.97%
  • Over 3 Month 9.81%
  • Over 6 Month -1.49%
  • Over 1 Year -9.66%

Dr. Reddy's Laboratories Key Statistics

P/E Ratio 23.7
PEG Ratio 0.3
Market Cap Cr 70,920
Price to Book Ratio 3.7
EPS 97.9
Dividend 0.7
Relative Strength Index 49.47
Money Flow Index 44.55
MACD Signal -42.19
Average True Range 86.98

Dr. Reddy's Laboratories Investment Rating

  • Master Rating:
  • Dr. Reddy's Laboratories has an operating revenue of Rs. 21,833.00 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 14% is healthy, ROE of 11% is good. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. It is currently FORMING a base in its weekly chart and is trading around 24% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 80 which is a GOOD score indicating consistency in earnings, a RS Rating of 41 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 105 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Dr. Reddy's Laboratories Financials
  • Indicator
  • Jun 2022
  • Mar 2022
  • Dec 2021
  • Sep 2021
  • Jun 2021
  • Mar 2021
  • Oper Rev Qtr Cr
  • 3,616
  • 3,632
  • 3,480
  • 3,823
  • 3,434
  • 3,351
  • Operating Expenses Qtr Cr
  • 3,051
  • 2,989
  • 2,866
  • 3,075
  • 2,872
  • 2,748
  • Operating Profit Qtr Cr
  • 580
  • 670
  • 614
  • 748
  • 562
  • 603
  • Depreciation Qtr Cr
  • 222
  • 205
  • 205
  • 207
  • 197
  • 211
  • Interest Qtr Cr
  • 10
  • 13
  • 8
  • 11
  • 7
  • 17
  • Tax Qtr Cr
  • 252
  • 147
  • 123
  • 200
  • 131
  • 145
  • Net Profit Qtr Cr
  • 500
  • 420
  • 341
  • 449
  • 413
  • 312

Dr. Reddy's Laboratories Technicals

EMA & SMA

Current Price
4260.8
2.5 (0.06%)
  • Bullish Moving Average
  • ___
  • 8
  • Bearish Moving Average
  • ___
  • 8
  • 20 Day
  • 4251.87
  • 50 Day
  • 4276.89
  • 100 Day
  • 4298.71
  • 200 Day
  • 4369.04
  • 20 Day
  • 4271.25
  • 50 Day
  • 4310.09
  • 100 Day
  • 4249.28
  • 200 Day
  • 4368.05

Dr. Reddy's Laboratories Resistance and Support

PIVOT
₹4257.4
Resistance
  • First Resistance
  • 4278.9
  • Second Resistance
  • 4299.5
  • Third Resistance
  • 4321
Support
  • First Resistance
  • 4236.8
  • Second Resistance
  • 4215.3
  • Third Resistance
  • 4194.7
  • RSI
  • 49.47
  • MFI
  • 44.55
  • MACD Single Line
  • -42.19
  • MACD
  • -37.82

Dr. Reddy's Laboratories Delivery and Volume

  • Period
  • NSE + BSE
    Volume Avg
  • NSE + BSE
    Delivery Volume Avg
  • NSE + BSE
    Delivery Volume %
  • Day
  • 409,580
  • 24,099,687
  • 58.84
  • Week
  • 378,914
  • 20,942,563
  • 55.27
  • 1 Month
  • 557,561
  • 24,354,260
  • 43.68
  • 6 Month
  • 548,578
  • 24,285,559
  • 44.27

Dr. Reddy's Laboratories Result Highlights

Dr. Reddy's Laboratories Synopsis

NSE-Medical-Diversified

Dr. Reddy's Labs is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 14405.20 Cr. and Equity Capital is Rs. 83.20 Cr. for the Year ended 31/03/2022. Dr. Reddy's Laboratories Ltd. is a Public Limited Listed company incorporated on 24/02/1984 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L85195TG1984PLC004507 and registration number is 004507.
  • Market Cap
  • 70,920
  • Sales
  • 14,602
  • Shares in Float
  • 12.15
  • No of funds
  • 718
  • Yield
  • 0.7
  • Book Value
  • 3.87
  • U/D Vol ratio
  • 1
  • LTDebt / Equity
  • Alpha
  • -0.05
  • Beta
  • 0.6

Dr. Reddy's Laboratories

  • Owner Name
  • Jun-22
  • Mar-22
  • Dec-21
  • Sep-21
  • Promoters
  • 26.71%
  • 26.72%
  • 26.72%
  • Mutual Funds
  • 14.21%
  • 14.12%
  • 12.47%
  • Insurance Companies
  • 10.72%
  • 10.23%
  • 9.37%
  • Foreign Portfolio Investors
  • 25.87%
  • 25.16%
  • 27.42%
  • Financial Institutions/ Banks
  • 0.02%
  • 0.12%
  • 0.11%
  • Individual Investors
  • 8.22%
  • 8.37%
  • 8.27%
  • Others
  • 14.25%
  • 15.28%
  • 15.64%

Dr. Reddy's Laboratories Management

  • Name
  • Designation
  • Mr. K Satish Reddy
  • Chairman
  • Mr. G V Prasad
  • Co-Chairman & Manag. Director
  • Mr. Leo Puri
  • Independent Director
  • Mr. Prasad R Menon
  • Independent Director
  • Ms. Shikha Sharma
  • Independent Director
  • Mr. Allan Oberman
  • Independent Director
  • Dr. Bruce L A Carter
  • Independent Director
  • Ms. Kalpana Morparia
  • Independent Director
  • Mr. Sridar Iyengar
  • Independent Director

Dr. Reddy's Laboratories Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Dr. Reddy's Laboratories Corporate Action

  • Date
  • Purpose
  • Remarks
  • 2022-07-28
  • Quarterly Results
  • 2022-05-19
  • Audited Results & Final Dividend
  • 2022-01-28
  • Quarterly Results
  • 2021-10-29
  • Quarterly Results
  • 2021-07-27
  • Quarterly Results

Dr. Reddy's Laboratories MF Shareholding

  • Name
  • Amount(cr)
  • SBI Nifty 50 ETF
  • 135323
  • SBI S&P BSE Sensex ETF
  • 72360
  • ICICI Prudential Balanced Advantage Fund Growth
  • 41742
  • UTI Nifty 50 Exchange Traded Fund
  • 33453
  • Mirae Asset Large Cap Fund Regular Growth
  • 32913

Dr. Reddy's Laboratories FAQs

What is Share Price of Dr. Reddy's Laboratories ?

Dr. Reddy's Laboratories share price is ₹4260 As on 14 August, 2022 | 10:50

What is the Market Cap of Dr. Reddy's Laboratories ?

The Market Cap of Dr. Reddy's Laboratories is ₹70920.3 Cr As on 14 August, 2022 | 10:50

What is the P/E ratio of Dr. Reddy's Laboratories ?

The P/E ratio of Dr. Reddy's Laboratories is 23.7 As on 14 August, 2022 | 10:50

What is the PB ratio of Dr. Reddy's Laboratories ?

The PB ratio of Dr. Reddy's Laboratories is 3.7 As on 14 August, 2022 | 10:50

What is Dr Reddys Laboratories's stock price CAGR?

Dr Reddys Laboratories stock price CAGR for 10 Years stands at 12%, 5 Years at 8%, 3 Years at 20%, and 1 Year at -2%.

What is the ROE of Dr Reddys Laboratories?

The ROE of Dr Reddys Laboratories is 11%.

Is Dr Reddys Laboratories a good investment?

Dr Reddy's Laboratories has an operating revenue of Rs. 20,442.10 Cr. on a trailing 12-month basis. Annual revenue growth of 7% is good, Pre-tax margin of 15% is great. As per analysts rating in the last 6 months, the recommendation is to HOLD Dr Reddys Laboratories.

Who is the CEO of Dr Reddys Laboratories

Erez Israeli is the Chief Executive Officer (CEO) at Dr Reddy's Laboratories since 1 Aug 2019.

Q1FY23